The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005, 102 :2892 2897. 4. Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K, Seyfert C, van Valen F, Pap T, Meinecke antigen peptide I: Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL and TRAIL induced apoptosis is cell cycle dependent. Arthritis Res Ther 2009, eleven :R16. 5. Korb A, Pavenst?dt H, Pap T: Cell death in rheumatoid arthritis. Apoptosis 2009, 14 :447 454. 6. Distler JH, Akhmetshina A, Dees C, J?ngel A, St?rzl M, Gay S, Pisetsky DS, Schett G, Distler O: Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum 2011, 63 :2067 2077. 7.

Castellana D, Zobairi F, Martinez MC, Panaro MA, Mitolo V, Freyssinet JM, Kunzelmann C: Membrane microvesicles as actors inside the establishment of the favorable prostatic tumoral niche: a purpose for activated fibroblasts and CX3CL1 CX3CR1 axis. Cancer Res 2009, 69 :785 793. P16 Elevated concentration mGluR3 of serum soluble LAG3 in systemic lupus erythematosus Seri Yu, Keishi Fujio, Kazuyoshi Ishigaki, Hirofumi Shoda, Tomohisa Okamura, Tanita Noor, Shuji Sumitomo, Kazuhiko Yamamoto Division of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113 0033, Japan Arthritis Research & Therapy 2012, 14 16 Background: In systemic lupus erythematosus, type I interferon and plasmacytoid DCs are supposed to play important roles. However, there are few evidences for pDCs activation in SLE.

Murine Cellular differentiation pDCs are reported to produce soluble LAG3 upon activation and pDCs are responsible for most of sLAG3 in mice serum. Therefore, serum sLAG3 concentration was examined in SLE and other autoimmune diseases. Materials and methods: This study enrolled 45 SLE patients who met ACR criteiria. Disease activity was rated using a SLE disease activity index. sLAG3 concentrations were measured by a quantitative sandwich enzyme immunoassay. Results: The ratio of sLAG3 concentration in SLE to control was 3. 10 / 1. 05, PM/DM to control was 1. 04 / 0. 08, and RA to control was 0. 77 / Page 26 of 54 Figure 1 sLAG3 concentrations in SLE and other autoimmune diseases measured by ELISA. 0. 14. In addition, sLAG3 concentrations showed a significant correlation with SLEDAI. Interestingly, elevation of sLAG3 was observed even in patients with SLEDAI _ 0.

These results suggested that sLAG3 could be a specific and novel marker for SLE. Conclusions: sLAG3 GSK-3 activation can be a novel marker for SLE. sLAG3 in sera of SLE patient may reflect the activation of pDCs. Because sLAG3 shows adjuvant effect when combined with active immunization, sLAG3 may contribute to the exacerbation of lupus. The association between elevated sLAG3, type I interferon signature and activation of pDCs should be investigated further. P17 GCIP, Id like HLH protein, negatively regulates cell proliferation of rheumatoid synovial cells via interaction with CBP Hidetoshi Fujita1,2, Minako Nakazawa1, Satoko Aratani1,3, Kusuki Nishioka3, Akiyoshi Fukamizu4, Toshihiro Nakajima.